NEW YORK — Biocept said on Tuesday that it has entered a collaboration with Quest Diagnostics to provide its Target Selector next generation-sequencing-based liquid biopsy lung cancer panel to Quest patients.
Under the agreement, Quest will begin to offer Target Selector in the fourth quarter this year. The blood-based test is intended for identifying genetic mutations to guide therapy in patients with advanced non-small cell lung cancer.
"Lung cancer is one of the most prevalent and deadliest cancers," Kristie Dolan, general manager, oncology franchise, Quest, said in a statement. "Better tools to aid in therapy selection and monitoring are urgently needed to improve patient outcomes, which is why we are so excited to work with Biocept on this focused test. Quest has the national scale, oncology expertise, and network provider relationships to broaden access to this important innovation in order to potentially improve care for patients in treatment for lung cancer."
"We are pleased to expand Biocept's relationship with Quest Diagnostics, as we believe its expertise and reach will allow us to serve more patients and potentially grow our customer base," said Michael Nall, president and CEO of Biocept. "Quest shares our focus on improving care for patients with lung cancer, and this agreement provides a strong collaborator to help us provide oncologists with the answers they need to create more personalized, responsive treatment plans for their patients."
Financial and other terms of the agreement were not disclosed.